Skip to main content

Table 4 Results of cytology and HR-HPV co-testing

From: Outcomes of prior cervical cytology and HR-HPV testing in women subsequently diagnosed with CIN1, CIN2/3, and invasive cervical cancer: a 4-year routine clinical experience after implementation of systematic training and quality control programs

Cytological interpretation HR-HPV testing Total
HC2 testing Genotyping
Negative (%) Positive (%) Negative (%) Positive (%) Negative (%) Positive (%)
CIN1 (n = 556)
 NILM 3 (1.5) 14 (7.2) 23 (6.4) 27 (7.5) 26 (4.7) 41 (7.4)
 ASC-US 20 (10.3) 49 (25.3) 40 (11.0) 91 (25.1) 60 (10.8) 140 (25.2)
 ASC-H 2 (1.0) 4 (2.1) 3 (0.8) 3 (0.8) 5 (0.9) 7 (1.3)
 LSIL 18 (9.3) 79 (40.7) 38 (10.5) 130 (35.9) 56 (10.1) 209 (37.6)
 HSIL 3 (1.5) 2 (1.0) 1 (0.3) 6 (1.7) 4 (0.7) 8 (1.4)
Total 46 (23.7) 148 (76.3) 105 (29.0) 257 (71.0) 151 (27.2) 405 (72.8)
CIN2/3 (n = 524)
 NILM 0 (0) 12 (5.6) 1 (0.3) 25 (8.0) 1 (0.2) 37 (7.1)
 ASC-US 2 (0.9) 33 (15.5) 7 (2.3) 53 (17.0) 9 (1.7) 86 (16.4)
 ASC-H 2 (0.9) 35 (16.4) 2 (0.6) 22 (7.1) 4 (0.8) 57 (10.9)
 LSIL 4 (1.9) 52 (24.4) 6 (1.9) 74 (23.8) 10 (1.9) 126 (24.0)
 HSIL 5 (2.3) 68 (31.9) 9 (2.9) 112 (36.0) 14 (2.7) 180 (34.4)
Total 13 (6.1) 200 (93.9) 25 (8.0) 286 (92.0) 38 (7.3) 486 (92.7)
ICC (n = 230)
 NILM 0 (0) 3 (7.3) 1 (0.5) 6 (3.2) 1 (0.4) 9 (3.9)
 Unsatisfactory 0 (0) 0 (0) 0 (0) 5 (2.6) 0 (0) 5 (2.2)
 ASC-US 1 (2.4) 3 (7.3) 3 (1.6) 15 (7.9) 4 (1.7) 18 (7.8)
 ASC-H 0 (0) 10 (24.4) 1 (0.5) 29 (15.3) 1 (0.4) 39 (17.0)
 LSIL 0 (0) 0 (0) 0 (0) 1 (0.5) 0 (0) 1 (0.4)
 HSIL 0 (0) 18 (43.9) 1 (0.5) 100 (52.9) 1 (0.4) 118 (51.3)
 AGC 0 (0) 0 (0) 2 (1.1) 3 (1.6) 2 (0.9) 3 (1.3)
 Cancer cells 0 (0) 6 (14.6) 3 (1.6) 19 (10.1) 3 (1.3) 25 (10.9)
Total 1 (2.4) 40 (97.6) 11 (5.8) 178 (94.2) 12 (5.2) 218 (94.8)
  1. HR-HPV high-risk human papillomavirus, CIN cervical intraepithelial neoplasia, ICC invasive cervical cancer, NILM negative for intraepithelial lesion or malignancy, ASC-US atypical squamous cells of undetermined significance, ASC-H atypical squamous cells-cannot exclude HSIL, LSIL low-grade squamous intraepithelial lesion, HSIL high-grade squamous intraepithelial lesion, AGC atypical glandular cells, HC2 Hybrid Capture 2